Kala Pharmaceuticals to Present at the Association for Research in

Kala Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology
2015 Annual Meeting
WALTHAM, Mass., May 1, 2015 – Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic
products based on its proprietary mucus-penetrating particle (MPP) technology, announced that a
poster has been selected for presentation at the Association for Research in Vision and Ophthalmology
(ARVO) 2015 Annual Meeting taking place May 3-7, 2015, in Denver, CO. Kala will present new
preclinical data for K106, a novel, topical Receptor Tyrosine Kinase inhibitor (RTKi) candidate designed
to potently and selectively block VEGF signaling. Information for the poster session is as follows:

Topical Delivery of a Novel Receptor Tyrosine Kinase Inhibitor (RTKi) via Mucus-Penetrating
Particles
Poster #: 2279 - B0184
Date/Time: Monday, May 4, 2015 from 2:45 PM to 5:30 PM MT
Session #/Title: 281, Novel targets and therapies
The ARVO Annual Meeting is the largest gathering of eye and vision researchers in the world and
provides a first look at science that could translate into clinical practice in the near future and potentially
transform diagnostics and treatments for blinding eye conditions.
About Kala Pharmaceuticals, Inc.
Kala is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments
for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucuspenetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced
delivery into ocular tissue by facilitating penetration through the tear film mucus. Beyond
ophthalmology, Kala’s MPP technology has potential applications in women’s reproductive health,
respiratory and gastrointestinal diseases, and other indications.
Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering, and is
backed by leading life sciences investors including Crown Venture Fund, Lux Capital, Polaris Partners,
Third Rock Ventures and Ysios Capital. For more information, please visit Kala’s website at
www.kalarx.com.
Contact:
Kari Watson
(781) 235-3060
[email protected]
or Hunter Marshall
(650) 342-1000
[email protected]
MacDougall Biomedical Communications
###